Literature DB >> 15879740

Altering metabolism.

Clifford T Pereira1, Kevin D Murphy, David N Herndon.   

Abstract

A significant proportion of the mortality and morbidity of severe burns is attributable to the ensuing hypermetabolic response. This response can last for as long as 1 year after injury and is associated with impaired wound healing, increased infection risks, erosion of lean body mass, hampered rehabilitation, and delayed reintegration of burn survivors into society. Pharmacologic and nonpharmacologic strategies may be used to reverse the catabolic effect of thermal injury. Nonpharmacologic strategies include early excision and wound closure of burn wound, aggressive treatment of sepsis, elevation of the environmental temperature to thermal neutrality (31.5 +/- 0.7 degrees C), high carbohydrate, high protein continuous enteral feeding, and early institution of resistive exercise programs. Pharmacologic modulators of the postburn hypermetabolic response may be achieved through the administration of recombinant human growth hormone, low-dose insulin infusion, use of the synthetic testosterone analog, oxandrolone, and beta blockade with propranolol. This review article discusses these modulators of postburn metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879740

Source DB:  PubMed          Journal:  J Burn Care Rehabil        ISSN: 0273-8481


  24 in total

1.  Burn treatment framework in Israel.

Authors:  Y Krieger; Y Shoham; A Levi; A Bogdanov-Beresovsky; E Silberstien; A Sagi
Journal:  Ann Burns Fire Disasters       Date:  2011-12-31

2.  Statistical and clinical analysis of alterations in glucose values after burns.

Authors:  M K Belba; E Petrela; A Belba; V Mano; G Belba
Journal:  Ann Burns Fire Disasters       Date:  2016-09-30

Review 3.  Adipose tissue: between the extremes.

Authors:  Alexandros Vegiopoulos; Maria Rohm; Stephan Herzig
Journal:  EMBO J       Date:  2017-06-16       Impact factor: 11.598

Review 4.  Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.

Authors:  Eduardo I Gus; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Burns       Date:  2019-12-15       Impact factor: 2.744

5.  Changes in cardiac physiology after severe burn injury.

Authors:  Felicia N Williams; David N Herndon; Oscar E Suman; Jong O Lee; William B Norbury; Ludwik K Branski; Ronald P Mlcak; Marc G Jeschke
Journal:  J Burn Care Res       Date:  2011 Mar-Apr       Impact factor: 1.845

6.  Retinol binding protein: marker for insulin resistance and inflammation postburn?

Authors:  Robert Kraft; David N Herndon; Gabriela A Kulp; Gabriel A Mecott; Heiko Trentzsch; Marc G Jeschke
Journal:  JPEN J Parenter Enteral Nutr       Date:  2011-11       Impact factor: 4.016

7.  Long-term propranolol use in severely burned pediatric patients: a randomized controlled study.

Authors:  David N Herndon; Noe A Rodriguez; Eva C Diaz; Sachin Hegde; Kristofer Jennings; Ronald P Mlcak; Jaipreet S Suri; Jong O Lee; Felicia N Williams; Walter Meyer; Oscar E Suman; Robert E Barrow; Marc G Jeschke; Celeste C Finnerty
Journal:  Ann Surg       Date:  2012-09       Impact factor: 12.969

Review 8.  Metabolic implications of severe burn injuries and their management: a systematic review of the literature.

Authors:  Bishara S Atiyeh; S William A Gunn; Saad A Dibo
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

Review 9.  Is propranolol of benefit in pediatric burn patients?

Authors:  Celeste C Finnerty; David N Herndon
Journal:  Adv Surg       Date:  2013

Review 10.  Insulin resistance postburn: underlying mechanisms and current therapeutic strategies.

Authors:  Gerd G Gauglitz; David N Herndon; Marc G Jeschke
Journal:  J Burn Care Res       Date:  2008 Sep-Oct       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.